Switzerland and Germany Are Main Suppliers on the Global Antisera Market

Pharmaceuticals, Medicinal Chemical And Botanical Products June 26, 2018
Author: Anna Sergeeva
Market Analyst

IndexBox has just published a new report "World: Antisera And Other Blood Fractions - Market Report. Analysis and Forecast to 2025". Here is a summary of the report’s key findings.

Global Consumption of Antisera Reached $76 Billion 

In 2016, the antisera and other blood fractions market grew by 12% to 76 billion USD. According to the IndexBox estimates, from 2007 to 2016 the global value of consumption of antisera and other blood fractions almost doubled, which was due to the rising demand in developing countries. 

In the immediate term, global antisera consumption is expected to retain its upward trend pattern, driven primarily by an increase of consumption in Asia region, where public health spending is expanding along with robust economy growth. On the other hand, some poor countries which need antisera as they suffer heavily from snake bites and envenoming, can’t afford it due to health budget shortages. Such countries, especially in Africa and Latin America, indicate significant market demand, which, however is limited by only a modest economy growth and potential. 

The U.S. and India Were the Main Consuming Countries of Antisera

In 2016, the countries with the highest consumption were the U.S. (25.5 billion USD) and India (17.6 billion USD), together comprising near 57% of global consumption. The other countries lagged far behind in terms of antisera consumption: Japan (4.9 billion USD), with 6% of total consumption, China (6%), the U.K. (4%), France (4%) and Canada (4%).

The highest annual growth rates of antisera and other blood fractions consumption from 2007 to 2016 were recorded in India, with +90.7% growth, China, with +46.2%, France, with +22.3% and Japan, with +18.7% growth. Following these rapid consumption growth rates, India significantly strengthened its share in terms of the global consumption from 0% in 2007 to 23% in 2016. China increased its share of consumption by +5 percentage points, Japan (+4 percentage points) and France (+3 percentage points) also increased their shares. By contrast, the share of the U.S. declined from 38% to 34% over the period under review.

Amongst the leading consuming countries, high levels of per capita consumption levels were recorded in the U.S. (79 USD/year in 2016) and Canada (75 USD/year), which were significantly higher than the world average of 10 USD/year. In these countries per capita consumption grew by +5.3% and +12.3%, respectively from 2007-2016. The annual growth of per capita consumption over the last nine years was the most notable in India, with +88.5% growth, China, with +45.9% growth, France, with +21.8% growth, Japan, with +18.8% growth.

Antisera Production Value Doubled over the Last Nine Years, Amounting to 78 billion USD

Production of antisera and other blood fractions reached 78 billion USD in 2016, expanding steadily from 2007 to 2016. Overall, the production value doubled from the level of 2007, rising on awerage by +8.1% per year over that period.

The U.S.,  Switzerland and India Were the Leading Producers of Antisera

The U.S. (28 billion USD), Switzerland (19 billion USD) and India (17 billion USD) were the key world antisera and other blood fractions producing countries, together making up 82% of global output in 2016. 

From 2007 to 2016, in Switzerland and the U.S. production levels increased by +13% and +5% per year, respectively, largely attributed to both strong domestic and global demand. 

In India, production of antisera and other blood fractions was not observed before 2011, however, over the period from 2011 to 2016, it grew from 9 billion USD to 17 billion USD, with a CAGR of +15.5 per year.

Antisera Remains a Highly Traded Global Commodity

Antisera and other blood fractions is a worldwide traded commodity with high trade intensity, determined mainly the substantial distance of many of the consumer countries from the centers of antisera production. In some of the consumer countries, the level of technological and economic development is insufficient for the production of antisera.

Antisera and other blood fractions will continue to be highly traded, however, in the medium term, annual growth will slow due to softening growth of antisera production.

Switzerland and Germany Were Main Suppliers of Antisera

In 2016, Switzerland (26.2  billion USD) and Germany (21.7 billion USD) were the main global suppliers of antisera and other blood fractions, with a combined share of 46% of global exports in value terms. They were followed by the U.S. (15%), the Netherlands (7%), Belgium (6%), Ireland and the U.K. (5% each). 

Ireland (+21.2% per year) and the U.K. (+32.7% per year) were among the fastest growing suppliers from 2007 to 2016. The remaining exporting countries also showed positive dynamics.

Ireland (+3 percentage point) and the UK (+4 percentage point) strengthened their positions in terms of the global export, while the shares sent from the U.S. (-2 percentage point), Germany (-2 percentage point), the Netherlands (-3 percentage point) and Switzerland (-3 percentage point) illustrated negative dynamics. The share of Belgium remained relatively stable throughout the analyzed period. 

Do you want to know more about the global antisera market? Get the latest trends and insight from our report. It includes a wide range of statistics on

  • antisera market share
  • antisera prices
  • antisera industry
  • antisera sales
  • antisera import
  • antisera export
  • antisera market forecast
  • antisera price forecast
  • key antisera producers

Source: World: Antisera And Other Blood Fractions - Market Report. Analysis and Forecast to 2025